Interest of Acridine Derivatives in the Anticancer Chemotherapy

Author(s): Martine Demeunynck, Franck Charmantray, Alain Martelli.

Journal Name: Current Pharmaceutical Design

Volume 7 , Issue 17 , 2001

Become EABM
Become Reviewer

Abstract:

DNA is considered as one of the main targets for anticancer drug design. The planar structure of acridines confers to the molecules the ability to bind DNA by intercalation and therefore to interfere with metabolic processes. A large number of natural alkaloids and synthetic acridine derivatives have been tested as anticancer agents. So far, a few molecules have entered clinical trials and have been approved for chemotherapy. The mechanisms of action are not fully understood. Cytotoxicity may be related to potent enzyme inhibition. Topoisomerase and telomerase activities may be strongly affected by acridines. The affinity of acridines for DNA has also been used to design new active compounds in which a DNA modifying group is tethered to the acridine nucleus. Acridine derivatives display other pharmacological properties such as antibacterial and antimalarial activities. They are also tested for Alzheimers disease.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 7
ISSUE: 17
Year: 2001
Page: [1703 - 1724]
Pages: 22
DOI: 10.2174/1381612013397131
Price: $58

Article Metrics

PDF: 27